Use of topical versus injectable anaesthesia for ShangRing circumcisions in men and boys in Kenya: Results from a randomized controlled trial.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 15 07 2018
accepted: 26 05 2019
entrez: 15 8 2019
pubmed: 15 8 2019
medline: 7 3 2020
Statut: epublish

Résumé

The ShangRing is a disposable, collar clamp circumcision device pre-qualified for use in men and boys 13 years and above. It has been shown to be faster than conventional circumcision with comparable adverse event (AE) rates and high client satisfaction. Voluntary medical male circumcision (VMMC) has been shown to dramatically reduce the risk of HIV acquisition in males. However, the fear of pain during circumcision is an important barrier to uptake. Use of topical anesthesia thus presents an opportunity to address this. We sought to evaluate the safety, effectiveness and acceptability of the use of topical anaesthesia with ShangRing circumcision of men and boys 10 years of age and above. Participants were randomised 2:1 to receive topical or injectable anaesthesia. All participants underwent no-flip ShangRing circumcision. The primary outcome measure was pain. Secondary outcomes included ease of use of topical versus injectable anaesthesia, AEs and participant satisfaction. Compared to the topical group, participants in the injectable group reported significantly more pain on administration of the anesthesia and at approximately 20 minutes after the procedure. In the topical group, sufficient anaesthesia with topical cream was not achieved in 21 (9.3%) cases before the start of the procedure; in another 6 (2.6%), supplementary injectable anaesthesia was required as the circumcision was being carried out. The AE rate was significantly lower (p<0.01) in the topical (0%) vs. the injectable group (4.2%). The most common AE was pain during the post-operative period. All AEs were managed conservatively and resolved without sequeale. 96.7% of participants were satisfied with the appearance of the healed penis and 100% would recommend the ShangRing to others. All seven male circumcision providers involved in the study preferred topical to injectable anaesthesia. Our results demonstrate the safety, improved clinical experience, effectiveness, and acceptability of the use of topical anaesthesia in ShangRing circumcision using the no-flip technique. Topical anaesthesia effectively eliminates needlestick pain from the clients' VMMC experience and thus has the potential to increase demand for the service. ClinicalTrials.gov NCT02390310.

Sections du résumé

BACKGROUND
The ShangRing is a disposable, collar clamp circumcision device pre-qualified for use in men and boys 13 years and above. It has been shown to be faster than conventional circumcision with comparable adverse event (AE) rates and high client satisfaction. Voluntary medical male circumcision (VMMC) has been shown to dramatically reduce the risk of HIV acquisition in males. However, the fear of pain during circumcision is an important barrier to uptake. Use of topical anesthesia thus presents an opportunity to address this.
OBJECTIVES
We sought to evaluate the safety, effectiveness and acceptability of the use of topical anaesthesia with ShangRing circumcision of men and boys 10 years of age and above.
METHODS
Participants were randomised 2:1 to receive topical or injectable anaesthesia. All participants underwent no-flip ShangRing circumcision. The primary outcome measure was pain. Secondary outcomes included ease of use of topical versus injectable anaesthesia, AEs and participant satisfaction.
RESULTS
Compared to the topical group, participants in the injectable group reported significantly more pain on administration of the anesthesia and at approximately 20 minutes after the procedure. In the topical group, sufficient anaesthesia with topical cream was not achieved in 21 (9.3%) cases before the start of the procedure; in another 6 (2.6%), supplementary injectable anaesthesia was required as the circumcision was being carried out. The AE rate was significantly lower (p<0.01) in the topical (0%) vs. the injectable group (4.2%). The most common AE was pain during the post-operative period. All AEs were managed conservatively and resolved without sequeale. 96.7% of participants were satisfied with the appearance of the healed penis and 100% would recommend the ShangRing to others. All seven male circumcision providers involved in the study preferred topical to injectable anaesthesia.
CONCLUSIONS
Our results demonstrate the safety, improved clinical experience, effectiveness, and acceptability of the use of topical anaesthesia in ShangRing circumcision using the no-flip technique. Topical anaesthesia effectively eliminates needlestick pain from the clients' VMMC experience and thus has the potential to increase demand for the service.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02390310.

Identifiants

pubmed: 31412032
doi: 10.1371/journal.pone.0218066
pii: PONE-D-18-17794
pmc: PMC6693766
doi:

Substances chimiques

Anesthetics 0

Banques de données

ClinicalTrials.gov
['NCT02390310']

Types de publication

Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0218066

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist. MB, MK, BC, and PM work for Bon Santé Consulting, which was contracted to provide data management and statistical support for the study. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The funder provided support in the form of salaries for authors MAB, PSL, RKL, DO, MO, NO, DM, and QDA via the grant that supported this work. The specific roles of these authors are articulated in the ‘author contributions’ section.

Références

AIDS Care. 2005 Feb;17(2):182-94
pubmed: 15763713
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
AIDS Behav. 2006 Jul;10(4):377-85
pubmed: 16736112
PLoS Med. 2006 Jul;3(7):e262
pubmed: 16822094
AIDS Behav. 2007 May;11(3):341-55
pubmed: 17053855
PLoS Med. 2006 Dec;3(12):e517
pubmed: 17194197
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
J Acquir Immune Defic Syndr. 2011 May 1;57(1):e7-12
pubmed: 21346586
J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):e127-34
pubmed: 21909032
PLoS Med. 2011 Nov;8(11):e1001132
pubmed: 22140367
AIDS. 2012 Mar 13;26(5):609-15
pubmed: 22210632
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e82-9
pubmed: 22343180
J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):49-55
pubmed: 22739133
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):617-21
pubmed: 23614991
AIDS. 2013 Nov 28;27(18):2899-907
pubmed: 23835501
J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):447-55
pubmed: 24583615
PLoS Med. 2014 May 06;11(5):e1001641
pubmed: 24800840
PLoS One. 2014 May 06;9(5):e85051
pubmed: 24802746
J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):430-7
pubmed: 25162816
Afr J AIDS Res. 2014;13(2):179-87
pubmed: 25174635
Zhonghua Nan Ke Xue. 2014 Dec;20(12):1113-9
pubmed: 25597180
PLoS One. 2015 Mar 30;10(3):e0121686
pubmed: 25822727
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S13-7
pubmed: 27331584
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S36-42
pubmed: 27331588
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S5-S12
pubmed: 27331591
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 4:S306-10
pubmed: 27404013
J Int AIDS Soc. 2017 Jul 12;20(1):21588
pubmed: 28715157

Auteurs

Quentin Awori (Q)

Population Council, Nairobi, Kenya.

Philip S Li (PS)

Center for Male Reproductive Medicine and Surgery, Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States of America.

Richard K Lee (RK)

Center for Male Reproductive Medicine and Surgery, Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States of America.

Daniel Ouma (D)

Population Council, Nairobi, Kenya.

Millicent Oundo (M)

Population Council, Nairobi, Kenya.

Mukhaye Barasa (M)

Bon Santé Consulting, Nairobi, Kenya.

Nereah Obura (N)

Population Council, Nairobi, Kenya.

David Mwamkita (D)

Population Council, Nairobi, Kenya.

Raymond Simba (R)

Homa Bay Teaching and Referral Hospital, Homa Bay, Kenya.

Jairus Oketch (J)

Homa Bay Teaching and Referral Hospital, Homa Bay, Kenya.

Nixon Nyangweso (N)

Homa Bay Teaching and Referral Hospital, Homa Bay, Kenya.

Mary Maina (M)

Vipingo Health Centre, Vipingo, Kenya.

Nicholas Kiswi (N)

Vipingo Health Centre, Vipingo, Kenya.

Michael Kirui (M)

Bon Santé Consulting, Nairobi, Kenya.

Betty Chirchir (B)

Bon Santé Consulting, Nairobi, Kenya.

Marc Goldstein (M)

Center for Male Reproductive Medicine and Surgery, Department of Urology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States of America.

Mark A Barone (MA)

Center for Biomedical Research, Population Council, New York, New York, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH